Real-time index price for TSX North American Pref Stock Index (STNU), along with buy or sell indicators, analysis, charts, ...

A %Healthcare company based out of Pennsylvania caused quite the stir on Tuesday after the company announced that it had ...

On Monday, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) entered into an exclusive license agreement with Biosion Inc for ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Fintel reports that on November 19, 2024, BTIG upgraded their outlook for Aclaris Therapeutics (NasdaqGS:ACRS) from Neutral ...

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first ...